ICAD (ICAD) Stock Price

ICAD Price

Delisted·Jul 16, 2025
3.87USD
Last traded price

Revenue at ICAD has contracted by 0.0% per year over the past 19 years to 19.61 M USD. For ICAD, the net margin of -28.6% is up versus -59.3% a few years ago. The consensus 12-month price target for ICAD is 3.57 USD, about 7.8% below where the stock trades today. Of 10 analysts, 6 rate the stock a buy — an overall Buy consensus.

ICAD stock price

Volume
Details

Stock Price

How to Read This Chart

This chart tracks the historical stock price of ICAD over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how ICAD stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing ICAD's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

ICAD Stock Price History
DateICAD Price
Access this data via the Eulerpool API

ICAD Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2019
31.34 M USD
-6.40 M USD
-13.55 M USD
Jan 1, 2020
29.70 M USD
-9.39 M USD
-17.61 M USD
Jan 1, 2021
33.64 M USD
-11.10 M USD
-11.25 M USD
Jan 1, 2022
27.94 M USD
-13.93 M USD
-13.66 M USD
Jan 1, 2023
17.32 M USD
-7.69 M USD
-4.85 M USD
Jan 1, 2024
19.61 M USD
-6.27 M USD
-5.62 M USD
Jan 1, 2025 (e)
19.97 M USD
-5.94 M USD
-4.48 M USD
Jan 1, 2026 (e)
22.33 M USD
-3.70 M USD
-3.03 M USD

ICAD Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 25, 2026, 10:35 PM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
201120122013201420152016201720182019202020212022202320242025e2026e
28.0028.0033.0043.0041.0026.0028.0025.0031.0029.0033.0027.0017.0019.0019.0022.00
16.6717.8630.30-4.65-36.597.69-10.7124.00-6.4513.79-18.18-37.0411.7615.79
71.4371.4369.7072.0970.7369.2364.2976.0077.4272.4172.7370.3782.3584.2184.2184.21
20.0020.0023.0031.0029.0018.0018.0019.0024.0021.0024.0019.0014.0016.0016.0018.53
-37.00-5.00-1.00-30.00-9.00-14.00-8.00-6.00-9.00-11.00-13.00-7.00-6.00-5.00-3.00
-132.14-17.86-3.03-73.17-34.62-50.00-32.00-19.35-31.03-33.33-48.15-41.18-31.58-26.32-13.64
-37.00-9.00-7.00-1.00-32.00-10.00-14.00-9.00-13.00-17.00-11.00-13.00-4.00-5.00-4.00-3.00
516.67-75.68-22.22-85.713,100.00-68.7540.00-35.7144.4430.77-35.2918.18-69.2325.00-20.00-25.00
10.7810.8110.8615.5415.7316.2116.5016.7719.3223.0725.1325.2626.3226.3526.3526.35
Details

Income Statement Key Figures

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales ICAD generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue ICAD retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare ICAD's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares ICAD has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against ICAD's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

ICAD stock margins

The ICAD margin analysis displays the gross margin, EBIT margin, as well as the profit margin of ICAD. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for ICAD.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2019
77.30 %
-20.41 %
-43.24 %
Jan 1, 2020
71.90 %
-31.61 %
-59.30 %
Jan 1, 2021
72.07 %
-33.01 %
-33.43 %
Jan 1, 2022
70.90 %
-49.85 %
-48.87 %
Jan 1, 2023
83.94 %
-44.40 %
-27.99 %
Jan 1, 2024
84.84 %
-31.97 %
-28.64 %
Jan 1, 2025 (e)
84.84 %
-29.74 %
-22.43 %
Jan 1, 2026 (e)
84.84 %
-16.55 %
-13.57 %

ICAD Stock Revenue, EBIT, Earnings per Share

The ICAD earnings per share therefore indicates how much revenue ICAD has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2019
1.62 USD
-0.33 USD
-0.70 USD
Jan 1, 2020
1.29 USD
-0.41 USD
-0.76 USD
Jan 1, 2021
1.34 USD
-0.44 USD
-0.45 USD
Jan 1, 2022
1.11 USD
-0.55 USD
-0.54 USD
Jan 1, 2023
0.66 USD
-0.29 USD
-0.18 USD
Jan 1, 2024
0.74 USD
-0.24 USD
-0.21 USD
Jan 1, 2025 (e)
0.76 USD
-0.23 USD
-0.17 USD
Jan 1, 2026 (e)
0.85 USD
-0.14 USD
-0.12 USD

ICAD business model & stock analysis

ICAD Inc is a leading company in medical imaging and automated image processing. It was founded in 1984 and is headquartered in Nashua, New Hampshire, USA.

ICAD SWOT Analysis

Strengths

ICAD Inc has a strong reputation in the industry and is known for its innovative products.

The company has a dedicated and skilled workforce, which contributes to its success.

ICAD Inc has a wide range of intellectual property rights and patents, providing a competitive advantage.

Weaknesses

ICAD Inc is heavily dependent on a few key clients, which poses a risk to its revenue stability.

The company has limited geographic reach, which limits its potential market and growth opportunities.

ICAD Inc faces challenges in terms of maintaining cost competitiveness compared to its larger competitors.

Opportunities

ICAD Inc can explore strategic partnerships or acquisitions to expand its market presence.

The growing demand for advanced technology solutions provides opportunities for ICAD Inc to develop new products.

The company can leverage its technology expertise to enter new industries and diversify its revenue streams.

Threats

ICAD Inc faces intense competition from both established players and emerging startups in the industry.

Economic downturns or market fluctuations can impact the company's sales and profitability.

Changes in regulations or policies may affect ICAD Inc's ability to operate or disrupt its supply chain.

ICAD Segments

ICAD Revenue by Segment (1/3)

  • 3 Years

  • 5 Years

  • Max

Products
Service Line Contracts
Supply Agreements
Professional Services
Others
Details
Date
Products
Service Line Contracts
Supply Agreements
Professional Services
Others
Jan 1, 2018
4.39 M USD
1.45 M USD
2.26 M USD
264,000.00 USD
389,000.00 USD
Jan 1, 2019
21.75 M USD
7.18 M USD
2.04 M USD
153,000.00 USD
222,000.00 USD
Jan 1, 2020
20.83 M USD
6.99 M USD
1.80 M USD
29,000.00 USD
45,000.00 USD
Jan 1, 2021
23.59 M USD
7.88 M USD
2.09 M USD
89,000.00 USD
0.00 USD

ICAD Revenue by Segment (2/3)

  • 3 Years

  • 5 Years

  • Max

Detection
Therapy
Details
Date
Detection
Therapy
Jan 1, 2018
5.49 M USD
0.00 USD
Jan 1, 2019
22.32 M USD
0.00 USD
Jan 1, 2020
22.00 M USD
7.70 M USD
Jan 1, 2021
22.02 M USD
11.62 M USD

ICAD Revenue by Segment (3/3)

  • 3 Years

  • 5 Years

  • Max

Therapy
Represents the Cancer Therapy segment
Details
Date
Therapy
Represents the Cancer Therapy segment
Jan 1, 2018
0.00 USD
4.08 M USD
Jan 1, 2019
9.02 M USD
0.00 USD
Jan 1, 2020
0.00 USD
0.00 USD
Jan 1, 2021
0.00 USD
0.00 USD

ICAD Eulerpool Fair Value

Details

Fair Value Estimate

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

ICAD historical P/E ratio, EBIT multiple, and P/S ratio

ICAD annual returns

Details

Annual Return

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

ICAD shares outstanding

The number of shares of ICAD was 26.35 M in 2025. This indicates how many shares ICAD is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2019
19.32 M Stocks
Jan 1, 2020
23.07 M Stocks
Jan 1, 2021
25.13 M Stocks
Jan 1, 2022
25.26 M Stocks
Jan 1, 2023
26.32 M Stocks
Jan 1, 2024
26.35 M Stocks
Jan 1, 2025 (e)
26.35 M Stocks
Jan 1, 2026 (e)
26.35 M Stocks

ICAD stock splits

In ICAD's history, there have been no stock splits.

Current ICAD forecasts and price targets in July 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy60.00 % (6)
Hold40.00 % (4)
Sell0.00 % (0)
12M Price Target
3.57
Last Price
3.87
Currency
USD
12M Return Potential
-7.75 %
LTM Return
0 %

ICAD Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
5/11/2026-0.03USD3.16 MUSD2026 Q1
3/17/2026-0.05USD5.50 MUSD2025 Q4
8/11/2025-0.06USD4.85 MUSD2025 Q2
11/13/2024-0.09USD4.61 MUSD2024 Q3
11/11/2024-0.09USD4.61 MUSD2024 Q3
5/13/2024-0.05USD4.39 MUSD2024 Q1
3/26/2024-0.05USD4.39 MUSD2023 Q4
11/8/2023-0.11USD8.20 MUSD2023 Q3
8/8/2023-0.11USD9.85 MUSD2023 Q2
11/10/2022-0.13USD8.19 MUSD2022 Q3

EESG©

Eulerpool ESG Scorecard© for the ICAD stock

21/100
24
Environment
16
Social
23
Governance
E

Environment

20
Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

ICAD shareholder structure

% Name
0.38109%
HANSAINVEST Hanseatische Investment GmbH
HANSAINVEST Hanseatische Investment GmbH
0.00000%
Qube Research & Technologies Ltd
Qube Research & Technologies Ltd
0.00000%
Squarepoint Capital LLP
Squarepoint Capital LLP
0.00000%
Oak Family Advisors, LLC
Oak Family Advisors, LLC
0.00000%
Portolan Capital Management, L.L.C.
Portolan Capital Management, L.L.C.
0.00000%
AMH Equity, Ltd.
AMH Equity, Ltd.

ICAD Executives and Management Board

DB

Ms. Dana Brown

(60)

Executive Chairman of the Board, President, Chief Executive Officer · since 2022

Compensation497,702.00 USD
JG

Mr. Jonathan Go

Chief Technology Officer

Compensation373,373.00 USD
EL

Mr. Eric Lonnqvist

Chief Financial Officer

Compensation363,716.00 USD
AS

Mr. Andrew Sassine

(60)

Independent Director

Compensation97,869.00 USD
SW

Dr. Susan Wood

(62)

Independent Director

Compensation96,452.00 USD

ICAD Supply Chain

ICAD Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
8 companies
#Name1M3M6M1Y2YTrend
1
0.20
0.52
0.80
0.90
0.85
#Name1M3M6M1Y2YTrend
1
-0.13
-0.64
-0.65
-0.69
-0.31
2
0.03
0.09
0.88
0.38
-0.15
3
Hologic
Supplier
0.23
-0.24
-0.08
-0.33
-0.09
4
0.30
0.47
0.81
0.17
0.08
5
0.25
0.62
0.83
0.67
0.08

Frequently asked questions about ICAD

ICAD Inc's business model primarily focuses on providing innovative medical solutions to enhance cancer detection and therapy planning. As a leading provider of advanced imaging and radiation therapy technologies, ICAD aims to deliver state-of-the-art solutions that enable healthcare professionals to accurately diagnose and treat patients. Their expertise lies in developing and commercializing computer-aided detection (CAD) and workflow solutions for medical imaging in specialties such as breast, lung, and colon health. With a mission to improve patient outcomes and healthcare efficiency, ICAD Inc strives to revolutionize cancer care through their cutting-edge technologies.

All fundamentals and in-depth analysis of ICAD

Our stock analysis for ICAD stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ICAD. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.